长春高新：注射用GenSci140注册临床试验申请获受理

Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Jinsai Pharmaceutical, has received the acceptance notice from the National Medical Products Administration for the clinical trial application of GenSci140, a new targeted antibody-drug conjugate developed independently by the company [1] Group 1 - Jinsai Pharmaceutical's GenSci140 is a novel targeted antibody-drug conjugate that specifically targets the folate receptor alpha subtype [1] - The acceptance of the clinical trial application marks a significant step in the development of GenSci140, indicating progress in the company's research and development efforts [1]